FR14C0069I2 - PHARMACEUTICAL COMPOSITION COMPRISING LURASIDONE - Google Patents

PHARMACEUTICAL COMPOSITION COMPRISING LURASIDONE

Info

Publication number
FR14C0069I2
FR14C0069I2 FR14C0069C FR14C0069C FR14C0069I2 FR 14C0069 I2 FR14C0069 I2 FR 14C0069I2 FR 14C0069 C FR14C0069 C FR 14C0069C FR 14C0069 C FR14C0069 C FR 14C0069C FR 14C0069 I2 FR14C0069 I2 FR 14C0069I2
Authority
FR
France
Prior art keywords
lurasidone
pharmaceutical composition
pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR14C0069C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0069(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of FR14C0069I1 publication Critical patent/FR14C0069I1/en
Application granted granted Critical
Publication of FR14C0069I2 publication Critical patent/FR14C0069I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR14C0069C 2005-05-26 2014-09-16 PHARMACEUTICAL COMPOSITION COMPRISING LURASIDONE Active FR14C0069I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005153508 2005-05-26
PCT/JP2006/310571 WO2006126681A1 (en) 2005-05-26 2006-05-26 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
FR14C0069I1 FR14C0069I1 (en) 2014-10-24
FR14C0069I2 true FR14C0069I2 (en) 2015-11-20

Family

ID=37452103

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0069C Active FR14C0069I2 (en) 2005-05-26 2014-09-16 PHARMACEUTICAL COMPOSITION COMPRISING LURASIDONE

Country Status (22)

Country Link
US (5) US8729085B2 (en)
EP (2) EP2422783B1 (en)
JP (2) JP4733120B2 (en)
KR (2) KR101552033B1 (en)
CN (2) CN102048734B (en)
AU (1) AU2006250340C1 (en)
BR (2) BRPI0611409B8 (en)
CA (1) CA2606510C (en)
CY (2) CY1114118T1 (en)
DK (2) DK1884242T3 (en)
ES (2) ES2408687T3 (en)
FR (1) FR14C0069I2 (en)
HK (1) HK1108379A1 (en)
HU (1) HUS1400051I1 (en)
LU (1) LU92550I2 (en)
MX (1) MX2007014872A (en)
NL (1) NL300690I2 (en)
PL (1) PL1884242T3 (en)
PT (1) PT1884242E (en)
RU (1) RU2398586C3 (en)
SI (1) SI1884242T1 (en)
WO (1) WO2006126681A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1886678B1 (en) * 2005-05-18 2017-04-19 Sumitomo Dainippon Pharma Co., Ltd. Stable tablet containing droxidopa
BRPI0611409B8 (en) * 2005-05-26 2021-05-25 Dainippon Sumitomo Pharma Co oral preparation comprising lurasidone
JP5401327B2 (en) * 2008-02-11 2014-01-29 大日本住友製薬株式会社 Tablets with improved dissolution
KR101618388B1 (en) 2008-06-13 2016-05-04 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Tablet quickly disintegrating in the oral cavity and method for producing the same
CN102170912A (en) * 2008-09-30 2011-08-31 大洋药品工业株式会社 Compression-molded preparation and method for producing the same
WO2010135396A2 (en) 2009-05-19 2010-11-25 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
CA2814840C (en) 2010-10-18 2018-08-28 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
WO2012063246A1 (en) * 2010-11-11 2012-05-18 Mapi Pharma Ltd. Amorphous form of lurasidone hydrochloride
WO2012107890A2 (en) * 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Crystalline forms of lurasidone hydrochloride
WO2012156981A1 (en) 2011-05-13 2012-11-22 Cadila Healthcare Limited Pharmaceutical compositions of lurasidone
US8981095B2 (en) 2011-07-28 2015-03-17 Mapi Pharma Ltd. Intermediate compounds and process for the preparation of lurasidone and salts thereof
CN102911169B (en) * 2011-08-02 2015-05-06 上海医药工业研究院 Method for preparing lurasidone
US20140243383A1 (en) 2011-08-24 2014-08-28 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
CN103446071B (en) * 2012-05-29 2017-12-19 江苏豪森药业集团有限公司 A kind of oral tablet and its production and use
CN102688209A (en) * 2012-06-21 2012-09-26 李兴惠 Lurasidone tablet and preparation method thereof
CN102688210A (en) * 2012-06-21 2012-09-26 李兴惠 Lurasidone medicine composition and preparation method
CN106074414B (en) * 2012-07-12 2019-01-18 成都康弘药业集团股份有限公司 A kind of oral disnitegration tablet and preparation method thereof containing Lurasidone
CN103006661B (en) * 2012-12-06 2015-02-18 江苏先声药物研究有限公司 Preparation containing lurasidone hydrochloride and preparation method thereof
US20150157628A1 (en) * 2013-12-11 2015-06-11 Saravanan Kannusamy Pharmaceutical compositions of Lurasidone and Process for preparation thereof
WO2016012898A1 (en) * 2014-07-25 2016-01-28 Lupin Limited Oral pharmaceutical composition of lurasidone
CN104606133A (en) * 2015-01-07 2015-05-13 万特制药(海南)有限公司 Oral lurasidone suspension and preparation method thereof
WO2016139683A2 (en) * 2015-03-05 2016-09-09 Jubilant Generics Limited Pharmaceutical compositions of lurasidone and process for preparing the same
DE102016205950A1 (en) * 2016-04-08 2017-10-12 Dietrich Seidel Means for use in inflammatory conditions of the mucous membranes
EP3318279A1 (en) * 2016-11-02 2018-05-09 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of lurasidone hydrochloride
CN108567758A (en) * 2017-03-08 2018-09-25 湖南洞庭药业股份有限公司 Lurasidone HCl tablet and preparation method thereof
CN107875122A (en) * 2017-12-17 2018-04-06 佛山市弘泰药物研发有限公司 A kind of Lurasidone HCl self-micro emulsion formulation and preparation method thereof
CN107854445A (en) * 2017-12-17 2018-03-30 佛山市弘泰药物研发有限公司 A kind of Lurasidone HCl dispersible tablet and preparation method thereof
CN107854446A (en) * 2017-12-19 2018-03-30 佛山市弘泰药物研发有限公司 A kind of Lurasidone HCl oral disintegrating tablet and preparation method thereof
EP3760206A4 (en) 2018-02-28 2021-11-03 Sumitomo Dainippon Pharma Co., Ltd. Aqueous suspension-type pharmaceutical preparation having controlled dissolution
EP3772992B1 (en) 2018-04-10 2022-05-18 Freshfoodz GmbH Method for conserving a meal prepared by heating, and for providing communal catering
JP2021518422A (en) * 2018-04-13 2021-08-02 サムヤン バイオファーマシューティカルズ コーポレイションＳａｍｙａｎｇ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ Pharmaceutical composition containing lenalidomide
CN115843243A (en) * 2020-08-26 2023-03-24 浙江华海药业股份有限公司 Lurasidone hydrochloride composition and preparation method thereof
AT17300U3 (en) * 2020-12-03 2022-02-15 G L Pharma Gmbh Solid oral pharmaceutical composition
CN116615184A (en) 2020-12-23 2023-08-18 住友制药株式会社 Oral solid preparation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600579A (en) * 1983-06-07 1986-07-15 Mallinckrodt, Inc. N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
US4551177A (en) 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
US4609675A (en) 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4837031A (en) 1987-09-17 1989-06-06 Mallinckrodt, Inc. Compositions containing ibuprofen
US5047246A (en) 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
US4911921A (en) 1989-02-02 1990-03-27 Mallinckrodt, Inc. High ibuprofen content granulations
US5104648A (en) 1989-02-02 1992-04-14 Mallinckrodt Specialty Chemicals Company High ibuprofen content granulations
JP2800953B2 (en) 1990-07-06 1998-09-21 住友製薬株式会社 New imide derivatives
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
MX9706449A (en) 1995-02-28 1997-11-29 Hoechst Marion Roussel Inc Pharmaceutical composition for piperidinoalkanol compounds.
JP4022269B2 (en) * 1995-05-26 2007-12-12 協和醗酵工業株式会社 Pharmaceutical composition
BR9814090A (en) 1997-10-20 2000-10-03 Dainippon Pharmaceutical Co Composition of rapidly soluble drugs
JP4063386B2 (en) 1998-01-29 2008-03-19 キッセイ薬品工業株式会社 Rapid-release oral pharmaceutical composition
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
EP1169024B1 (en) * 1999-03-31 2005-12-21 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US6586617B1 (en) 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives
AU2001246861A1 (en) * 2000-04-10 2001-10-23 Sumitomo Pharmaceuticals Co. Ltd. Sustained release preparations
DE60138722D1 (en) * 2000-09-22 2009-06-25 Dainippon Sumitomo Pharma Co ORAL PREPARATIONS WITH ADVANTAGEOUS COATING CHARACTERISTICS
JP4250423B2 (en) 2001-03-19 2009-04-08 大日本住友製薬株式会社 Aryl-substituted alicyclic compound and pharmaceutical composition containing the same
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
EP2295061A1 (en) * 2002-08-22 2011-03-16 Dainippon Sumitomo Pharma Co., Ltd. Agent for treatment of schizophrenia
JP2006514687A (en) 2002-08-30 2006-05-11 ファルマシア コーポレイション Pharmaceutical solid dosage form with reproducible drug release characteristics
JPWO2004078173A1 (en) * 2003-02-05 2006-06-08 塩野義製薬株式会社 Tablets with improved dissolution
DK3260117T3 (en) 2003-09-12 2019-07-01 Amgen Inc QUICKLY Dissolving Formulation Containing CINACALCET HCL
JP4740740B2 (en) 2003-12-09 2011-08-03 大日本住友製薬株式会社 Drug-containing particles and solid preparation containing the particles
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
BRPI0611409B8 (en) 2005-05-26 2021-05-25 Dainippon Sumitomo Pharma Co oral preparation comprising lurasidone

Also Published As

Publication number Publication date
SI1884242T1 (en) 2013-07-31
LU92550I2 (en) 2015-11-02
CA2606510A1 (en) 2006-11-30
MX2007014872A (en) 2008-02-15
KR20130122019A (en) 2013-11-06
BRPI0611409A8 (en) 2015-12-15
PT1884242E (en) 2013-05-21
CA2606510C (en) 2014-07-22
CN102048734B (en) 2013-11-20
CN101184489B (en) 2011-01-19
US20090143404A1 (en) 2009-06-04
RU2398586C3 (en) 2017-10-04
HK1108379A1 (en) 2008-05-09
US8883794B2 (en) 2014-11-11
JPWO2006126681A1 (en) 2008-12-25
DK2422783T3 (en) 2015-05-11
US20150056284A1 (en) 2015-02-26
US8729085B2 (en) 2014-05-20
US20150265611A1 (en) 2015-09-24
CY2014039I1 (en) 2016-06-22
CY2014039I2 (en) 2016-06-22
EP1884242A4 (en) 2009-07-01
RU2398586C2 (en) 2010-09-10
CN102048734A (en) 2011-05-11
KR101552033B1 (en) 2015-09-09
ES2408687T3 (en) 2013-06-21
WO2006126681A1 (en) 2006-11-30
JP2011126915A (en) 2011-06-30
AU2006250340B2 (en) 2012-02-09
BR122020005056A2 (en) 2010-11-23
AU2006250340C1 (en) 2014-06-12
CY1114118T1 (en) 2016-06-22
AU2006250340A1 (en) 2006-11-30
HUS1400051I1 (en) 2016-10-28
FR14C0069I1 (en) 2014-10-24
US20140235651A1 (en) 2014-08-21
EP1884242B1 (en) 2013-04-17
KR20080012306A (en) 2008-02-11
JP4733120B2 (en) 2011-07-27
US9907794B2 (en) 2018-03-06
US20180161322A1 (en) 2018-06-14
BR122020005056A8 (en) 2022-11-22
RU2007148997A (en) 2009-07-10
ES2535478T3 (en) 2015-05-12
DK1884242T3 (en) 2013-05-06
EP2422783A1 (en) 2012-02-29
EP1884242A1 (en) 2008-02-06
BRPI0611409A2 (en) 2010-11-23
NL300690I2 (en) 2017-11-02
EP2422783B1 (en) 2015-04-08
PL1884242T3 (en) 2013-09-30
BRPI0611409B1 (en) 2020-12-29
JP5285105B2 (en) 2013-09-11
BRPI0611409B8 (en) 2021-05-25
US9555027B2 (en) 2017-01-31
KR101380088B1 (en) 2014-04-10
CN101184489A (en) 2008-05-21
BR122020005056B1 (en) 2023-01-10

Similar Documents

Publication Publication Date Title
FR14C0069I2 (en) PHARMACEUTICAL COMPOSITION COMPRISING LURASIDONE
DK1962873T3 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING OXALATE-REDUCING BACTERIA
ITBO20050123A1 (en) GASTRORESISTIC PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINA
BRPI0511900A (en) pharmaceutical compositions
NO20075628L (en) Pharmaceutical formulations
DK1940467T3 (en) Long-release drug composition
DK1957073T3 (en) PHARMACEUTICAL
DK1725218T3 (en) Pharmaceutical composition comprising pimobendan
NL1029431A1 (en) Liquid pesticide compositions.
BRPI0715712A2 (en) PHARMACEUTICAL COMPOSITION
BRPI0614205A2 (en) compound, pharmaceutical composition and compound use
FR18C1032I2 (en) ANTI-FGF23 ANTIBODIES AND PHARMACEUTICAL COMPOSITION COMPRISING IT
FR2881643B1 (en) MATIFYING COMPOSITION COMPRISING PERLITE
BRPI0719398A2 (en) Pharmaceutical composition.
BRPI0719393A2 (en) Pharmaceutical Composition
ATE453384T1 (en) NEW DOSAGE FORMULATION
DK3072507T3 (en) PHARMACEUTICAL COMPOSITIONS FOR GLUCOCORTICODE SUBSTITUTION THERAPY
BRPI0716445A2 (en) pharmaceutical composition
DK1741339T3 (en) Pesticide composition
BRPI0720234A2 (en) PHARMACEUTICAL COMPOSITION
DK1587478T3 (en) PHARMACEUTICAL COMPOSITION
DE602006000877D1 (en) emulsion composition
BRPI0615630A2 (en) pharmaceutical composition and use of sertindole
MA28603B1 (en) ANTIMYCOBACTERIAL PHARMACEUTICAL COMPOSITION
BRPI0614413A2 (en) compound and pharmaceutical composition